Citations (102)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Mina Hosseini, Zahra Habibi, Narges Hosseini, Sina Abdoli & Nima Rezaei. (2022) Preclinical studies of chimeric antigen receptor-modified natural killer cells in cancer immunotherapy: a review. Expert Opinion on Biological Therapy 22:3, pages 349-366.
Read now
Read now
Kajal Chaudhry, Ehsan Dowlati & Catherine M. Bollard. (2021) Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy. Expert Review of Clinical Immunology 17:6, pages 643-659.
Read now
Read now
Lisa Marie Reindl, Nawid Albinger, Tobias Bexte, Stephan Müller, Jessica Hartmann & Evelyn Ullrich. (2020) Immunotherapy with NK cells: recent developments in gene modification open up new avenues. OncoImmunology 9:1.
Read now
Read now
Jose M. Ayuso, Regan Truttschel, Max M. Gong, Mouhita Humayun, Maria Virumbrales-Munoz, Ross Vitek, Mildred Felder, Stephen D. Gillies, Paul Sondel, Kari B. Wisinski, Manish Patankar, David J. Beebe & Melissa C. Skala. (2019) Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model. OncoImmunology 8:3.
Read now
Read now
Laurent Boissel, Monica Betancur, Weiquan Lu, Daniela Krause, Richard Van Etten, Winfried Wels & Hans Klingemann. (2013) Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. OncoImmunology 2:10.
Read now
Read now
Articles from other publishers (97)
Charlotte Hinnekens, Stefaan C. De Smedt, Juan C. Fraire & Kevin Braeckmans. (2023) Non-viral engineering of NK cells. Biotechnology Advances 68, pages 108212.
Crossref
Crossref
Behnam Azadpour, Nazli Aharipour, Amirhosein Paryab, Hamed Omid, Sorosh Abdollahi, Hamidreza Madaah Hosseini, Adrine Malek Khachatourian, Muhammet S. Toprak & Alexander M. Seifalian. (2023) Magnetically-assisted viral transduction (magnetofection) medical applications: An update. Biomaterials Advances 154, pages 213657.
Crossref
Crossref
Yalan Zhang, Weilin Zhou, Jiangping Yang, Jinrong Yang & Wei Wang. (2023) Chimeric antigen receptor engineered natural killer cells for cancer therapy. Experimental Hematology & Oncology 12:1.
Crossref
Crossref
Qi Xiong, Jiao Zhu, Yong Zhang & Hongxin Deng. (2023) CAR-NK cell therapy for glioblastoma: what to do next?. Frontiers in Oncology 13.
Crossref
Crossref
Takashi Nakamura, Taisei Nakade, Yusuke Sato & Hideyoshi Harashima. (2023) Delivering mRNA to a human NK cell line, NK-92 cells, by lipid nanoparticles. International Journal of Pharmaceutics 636, pages 122810.
Crossref
Crossref
Emanuela Senjor, Meng-Wei Ko, Kawaljit Kaur, Po-Chun Chen, Barbara Breznik, Nishant Chovatiya, Janko Kos & Anahid Jewett. 2023. NK Cells in Cancer Immunotherapy: Successes and Challenges. NK Cells in Cancer Immunotherapy: Successes and Challenges
3
25
.
Sandro Matosevic. 2023. NK Cells in Cancer Immunotherapy: Successes and Challenges. NK Cells in Cancer Immunotherapy: Successes and Challenges
65
81
.
Gils Roex, Diana Campillo-Davo, Donovan Flumens, Philip Anthony Gilbert Shaw, Laurens Krekelbergh, Hans De Reu, Zwi N. Berneman, Eva Lion & Sébastien Anguille. (2022) Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. Journal of Translational Medicine 20:1.
Crossref
Crossref
Xiao Wang, Xuejiao Yang, Xiang Yuan, Wenbo Wang & Yueying Wang. (2022) Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential. Experimental Hematology & Oncology 11:1.
Crossref
Crossref
Ayda Baghery Saghchy Khorasani, Amir-Mohammad Yousefi & Davood Bashash. (2022) CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges. International Immunopharmacology 110, pages 109041.
Crossref
Crossref
Ruyan Rahnama, Ilias Christodoulou & Challice L. Bonifant. (2022) Gene-Based Natural Killer Cell Therapies for the Treatment of Pediatric Hematologic Malignancies. Hematology/Oncology Clinics of North America 36:4, pages 745-768.
Crossref
Crossref
Fiorella Rossi, Nathaniel Fredericks, Andrew Snowden, Michael J. Allegrezza & Uriel Y. Moreno-Nieves. (2022) Next Generation Natural Killer Cells for Cancer Immunotherapy. Frontiers in Immunology 13.
Crossref
Crossref
Fang Fang, Siqi Xie, Minhua Chen, Yutong Li, Jingjing Yue, Jie Ma, Xun Shu, Yongge He, Weihua Xiao & Zhigang Tian. (2022) Advances in NK cell production. Cellular & Molecular Immunology 19:4, pages 460-481.
Crossref
Crossref
Itziar Gómez-Aguado, Julen Rodríguez-Castejón, Marina Beraza-Millor, Alicia Rodríguez-Gascón, Ana del Pozo-Rodríguez & María Ángeles Solinís. 2022. mRNA-Based Therapeutics. mRNA-Based Therapeutics
207
293
.
Musga Qureischi, Julia Mohr, Estibaliz Arellano-Viera, Sarah Elspeth Knudsen, Farrukh Vohidov & Andoni Garitano-Trojaola. 2022. mRNA-Based Therapeutics. mRNA-Based Therapeutics
1
54
.
Gulzar Ahmad & Mansoor M. Amiji. 2022. Cancer Immunology and Immunotherapy. Cancer Immunology and Immunotherapy
237
265
.
Alireza Shokouhifar, Javad Firouzi, Masoumeh Nouri, Gholamreza Anani Sarab & Marzieh Ebrahimi. (2021) NK cell upraise in the dark world of cancer stem cells. Cancer Cell International 21:1.
Crossref
Crossref
Paresh Vishwasrao, Susanta K. Hui, D. Lynne Smith & Vishal Khairnar. (2021) Role of NK Cells in Cancer and Immunotherapy. Onco 1:2, pages 158-175.
Crossref
Crossref
Ali Bashiri Dezfouli, Mina Yazdi, Alan Graham Pockley, Mohammad Khosravi, Sebastian Kobold, Ernst Wagner & Gabriele Multhoff. (2021) NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development. Cells 10:12, pages 3390.
Crossref
Crossref
Gabrielle M. Robbins, Minjing Wang, Emily J. Pomeroy & Branden S. Moriarity. (2021) Nonviral genome engineering of natural killer cells. Stem Cell Research & Therapy 12:1.
Crossref
Crossref
Jan D. Beck, Daniel Reidenbach, Nadja Salomon, Ugur Sahin, Özlem Türeci, Mathias Vormehr & Lena M. Kranz. (2021) mRNA therapeutics in cancer immunotherapy. Molecular Cancer 20:1.
Crossref
Crossref
Ilias Christodoulou, Won Jin Ho, Andrew Marple, Jonas W Ravich, Ada Tam, Ruyan Rahnama, Adam Fearnow, Cambrynne Rietberg, Sean Yanik, Elena E Solomou, Ravi Varadhan, Michael A Koldobskiy & Challice L Bonifant. (2021) Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. Journal for ImmunoTherapy of Cancer 9:12, pages e003894.
Crossref
Crossref
Kellsye P. Fabian & James W. Hodge. (2021) The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy. Molecular Therapy - Oncolytics 23, pages 266-276.
Crossref
Crossref
Rachel Ringquist, Delta Ghoshal, Ritika Jain & Krishnendu Roy. (2021) Understanding and improving cellular immunotherapies against cancer: From cell-manufacturing to tumor-immune models. Advanced Drug Delivery Reviews 179, pages 114003.
Crossref
Crossref
Melita IrvingEvripidis LanitisDenis MiglioriniZoltán IvicsSonia Guedan. (2021) Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells. Human Gene Therapy 32:19-20, pages 1044-1058.
Crossref
Crossref
Rakan El-Mayta, Zijing Zhang, Alex G. Hamilton & Michael J. Mitchell. (2021) Delivery technologies to engineer natural killer cells for cancer immunotherapy. Cancer Gene Therapy 28:9, pages 947-959.
Crossref
Crossref
Peter Chockley, Sagar L. Patil & Stephen Gottschalk. (2021) Transient blockade of TBK1/IKKε allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors. Cytotherapy 23:9, pages 787-792.
Crossref
Crossref
Hui Lu, Xiaoyan Zhao, Ziying Li, Yu Hu & Huafang Wang. (2021) From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies. Frontiers in Oncology 11.
Crossref
Crossref
Faroogh Marofi, Marwan Mahmood Saleh, Heshu Sulaiman Rahman, Wanich Suksatan, Moaed E. Al-Gazally, Walid Kamal Abdelbasset, Lakshmi Thangavelu, Alexei Valerievich Yumashev, Ali Hassanzadeh, Mahboubeh Yazdanifar, Roza Motavalli, Yashwant Pathak, Adel Naimi, Behzad Baradaran, Marzieh Nikoo & Farhad Motavalli Khiavi. (2021) CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies. Stem Cell Research & Therapy 12:1.
Crossref
Crossref
Faroogh Marofi, Alaa S. Al-Awad, Heshu Sulaiman Rahman, Alexander Markov, Walid Kamal Abdelbasset, Yulianna Ivanovna Enina, Mahnaz Mahmoodi, Ali Hassanzadeh, Mahboubeh Yazdanifar, Max Stanley Chartrand & Mostafa Jarahian. (2021) CAR-NK Cell: A New Paradigm in Tumor Immunotherapy. Frontiers in Oncology 11.
Crossref
Crossref
Faroogh Marofi, Heshu Sulaiman Rahman, Lakshmi Thangavelu, Aleksey Dorofeev, Favian Bayas-Morejón, Naghmeh Shirafkan, Navid Shomali, Max Stanley Chartrand, Mostafa Jarahian, Ghasem Vahedi, Rebar N. Mohammed, Somayeh Shahrokh, Morteza Akbari & Farhad Motavalli Khiavi. (2021) Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. Stem Cell Research & Therapy 12:1.
Crossref
Crossref
Rih-Sheng Huang, Min-Chi Lai, Hsin-An Shih & Steven Lin. (2021) A robust platform for expansion and genome editing of primary human natural killer cells. Journal of Experimental Medicine 218:3.
Crossref
Crossref
Synat Kang, Xuefeng Gao, Li Zhang, Erna Yang, Yonghui Li & Li Yu. (2021) The Advances and Challenges of NK Cell-Based Cancer Immunotherapy. Current Oncology 28:2, pages 1077-1093.
Crossref
Crossref
Paula Schmidt, Martin J. Raftery & Gabriele Pecher. (2021) Engineering NK Cells for CAR Therapy—Recent Advances in Gene Transfer Methodology. Frontiers in Immunology 11.
Crossref
Crossref
Utkarsh H. Acharya & Roland B. Walter. (2020) Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML). Cancers 12:12, pages 3617.
Crossref
Crossref
Keerthana Shankar, Christian M. Capitini & Krishanu Saha. (2020) Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies. Stem Cell Research & Therapy 11:1.
Crossref
Crossref
Ahmet Yilmaz, Hanwei Cui, Michael A. Caligiuri & Jianhua Yu. (2020) Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Lara Herrera, Manel Juan & Cristina Eguizabal. (2020) Purification, Culture, and CD19‐CAR Lentiviral Transduction of Adult and Umbilical Cord Blood NK Cells. Current Protocols in Immunology 131:1.
Crossref
Crossref
Wen-Ying Lin, Hsin-Hui Wang, Yi-Wei Chen, Chun-Fu Lin, Hueng-Chuen Fan & Yi-Yen Lee. (2020) Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies. International Journal of Molecular Sciences 21:22, pages 8655.
Crossref
Crossref
Jufeng XiaShuichi MinaminoKazuma Kuwabara. (2020) CAR-expressing NK cells for cancer therapy: a new hope. BioScience Trends 14:5, pages 354-359.
Crossref
Crossref
Meisam Naeimi Kararoudi, Brian P. Tullius, Nitin Chakravarti, Emily J. Pomeroy, Branden S. Moriarity, Kathie Beland, Aurelien B.L. Colamartino, Elie Haddad, Yaya Chu, Mitchell S. Cairo & Dean A. Lee. (2020) Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity. Seminars in Hematology 57:4, pages 201-212.
Crossref
Crossref
Qian Liu, Yingxi Xu, Junli Mou, Kejing Tang, Xuehang Fu, Yihui Li, Yanyan Xing, Qing Rao, Haiyan Xing, Zheng Tian, Min Wang & Jianxiang Wang. (2020) Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19+ malignancy in a mouse model. Cytotherapy 22:10, pages 552-562.
Crossref
Crossref
Jai Rautela, Elliot Surgenor & Nicholas D. Huntington. (2020) Drug target validation in primary human natural killer cells using CRISPR RNP. Journal of Leukocyte Biology 108:4, pages 1397-1408.
Crossref
Crossref
Aaron J. Wilk, Nancy Lynn-Benner Weidenbacher, Rosemary VergaraOle A. W. HaabethRonald LevyRobert M. Waymouth, Paul A. Wender & Catherine A. Blish. (2020) Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy. Blood Advances 4:17, pages 4244-4255.
Crossref
Crossref
Arezoo Jamali, Jamshid Hadjati, Zahra Madjd, Hamid Reza Mirzaei, Frederic B. Thalheimer, Shiwani Agarwal, Halvard Bonig, Evelyn Ullrich & Jessica Hartmann. (2020) Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4. Frontiers in Immunology 11.
Crossref
Crossref
Dashnamoorthy Ravi, Saheli Sarkar, Sneha Purvey, Frank Passero, Afshin Beheshti, Ying Chen, Maisarah Mokhtar, Kevin David, Tania Konry & Andrew M. Evens. (2019) Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma. Leukemia 34:5, pages 1291-1304.
Crossref
Crossref
Luke Riggan, Andrew D. Hildreth, Marion Rolot, Yung-Yu Wong, William Satyadi, Ryan Sun, Christopher Huerta & Timothy E. O’Sullivan. (2020) CRISPR-Cas9 Ribonucleoprotein-Mediated Genomic Editing in Mature Primary Innate Immune Cells. Cell Reports 31:7, pages 107651.
Crossref
Crossref
Lili Yang, Changxin Huang, Congjie Wang, Siyu Zhang, Zhaoyang Li, Ying Zhu, Da Li, Lanlan Gao, Zuanmin Ge, Meng Su, Xi Feng & Yongqiang Li. (2020) Overexpressed CXCR4 and CCR7 on the surface of NK92 cell have improved migration and anti-tumor activity in human colon tumor model. Anti-Cancer Drugs 31:4, pages 333-344.
Crossref
Crossref
C. Quintarelli, S. Sivori, S. Caruso, S. Carlomagno, M. Falco, I. Boffa, D. Orlando, M. Guercio, Z. Abbaszadeh, M. Sinibaldi, S. Di Cecca, A. Camera, B. Cembrola, A. Pitisci, M. Andreani, L. Vinti, S. Gattari, F. Del Bufalo, M. Algeri, G. Li Pira, A. Moseley, B. De Angelis, L. Moretta & F. Locatelli. (2019) Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia. Leukemia 34:4, pages 1102-1115.
Crossref
Crossref
Stephan Müller, Tobias Bexte, Veronika Gebel, Franziska Kalensee, Eva Stolzenberg, Jessica Hartmann, Ulrike Koehl, Axel Schambach, Winfried S. Wels, Ute Modlich & Evelyn Ullrich. (2020) High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia. Frontiers in Immunology 10.
Crossref
Crossref
Lei Huang, Luyao Zhang, Weiwei Li, Shiqiang Li, Jianguo Wen, Hangwen Li & Zhongmin Liu. 2022. mRNA Vaccines. mRNA Vaccines
147
166
.
L. Herrera, S. Santos, M. A. Vesga, J. Anguita, I. Martin-Ruiz, T. Carrascosa, M. Juan & C. Eguizabal. (2019) Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells. Scientific Reports 9:1.
Crossref
Crossref
Lauren C. Fleischer, H. Trent Spencer & Sunil S. Raikar. (2019) Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions. Journal of Hematology & Oncology 12:1.
Crossref
Crossref
Stefanie R. Bailey & Marcela V. Maus. (2019) Gene editing for immune cell therapies. Nature Biotechnology 37:12, pages 1425-1434.
Crossref
Crossref
Kwang-Soo Kim, Jun-Hyeok Han, Jung-Hoon Park, Hyung-Keun Kim, Seung Hee Choi, Gyeong Ryeong Kim, Haengseok Song, Hee Jung An, Dong Keun Han, Wooram Park & Kyung-Soon Park. (2019) Multifunctional nanoparticles for genetic engineering and bioimaging of natural killer (NK) cell therapeutics. Biomaterials 221, pages 119418.
Crossref
Crossref
Simona Sivori, Raffaella Meazza, Concetta Quintarelli, Simona Carlomagno, Mariella Della Chiesa, Michela Falco, Lorenzo Moretta, Franco Locatelli & Daniela Pende. (2019) NK Cell-Based Immunotherapy for Hematological Malignancies. Journal of Clinical Medicine 8:10, pages 1702.
Crossref
Crossref
Xiang Ao, Yu Yang, Weiqiang Li, Yan Tan, Wei Guo, Luoquan Ao, Xiao He, Xiaofeng Wu, Jianchuan Xia, Xiang Xu & Jianxin Guo. (2019) Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer. Journal of Immunotherapy 42:8, pages 284-296.
Crossref
Crossref
Luyao Wang, Mei Dou, Qingxia Ma, Ruixue Yao & Jia Liu. (2019) Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges. International Immunopharmacology 74, pages 105695.
Crossref
Crossref
Yasmin Granot-Matok, Edo Kon, Niels Dammes, Gilad Mechtinger & Dan Peer. (2019) Therapeutic mRNA delivery to leukocytes. Journal of Controlled Release 305, pages 165-175.
Crossref
Crossref
Tiziano Ingegnere, Francesca Romana Mariotti, Andrea Pelosi, Concetta Quintarelli, Biagio De Angelis, Nicola Tumino, Francesca Besi, Claudia Cantoni, Franco Locatelli, Paola Vacca & Lorenzo Moretta. (2019) Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing. Frontiers in Immunology 10.
Crossref
Crossref
Davide Bernareggi, Somayeh Pouyanfard & Dan S. Kaufman. (2019) Development of innate immune cells from human pluripotent stem cells. Experimental Hematology 71, pages 13-23.
Crossref
Crossref
Clara Di Vito, Joanna Mikulak, Elisa Zaghi, Silvia Pesce, Emanuela Marcenaro & Domenico Mavilio. (2019) NK cells to cure cancer. Seminars in Immunology 41, pages 101272.
Crossref
Crossref
Ю. Е. Кравченко, Д. И. Гагаринская, Е. И. Фролова & С. П. Чумаков. (2018) Экспрессия химерного антигенного рецептора в натуральных киллерах линии NK-92 путем трансдукции лентивирусными частицами, псевдотипированными поверхностными гликопротеинами вакцинного штамма вируса кори. Вестник Российского Государственного медицинского университета:6, pages 170-176.
Crossref
Crossref
Yu.E. Kravchenko, D.I. Gagarinskaya, E.I. Frolova & S.P. Chumakov. (2018) Chimeric antigen receptor expression in natural killer cell line NK-92 by transduction with lentiviral particles pseudotyped with the surface glycoproteins of the measles virus vaccine strain. Bulletin of Russian State Medical University:6, pages 155-161.
Crossref
Crossref
Katharina Kriegsmann, Mark Kriegsmann, Michael von Bergwelt-Baildon, Martin Cremer & Mathias Witzens-Harig. (2018) NKT cells - New players in CAR cell immunotherapy?. European Journal of Haematology 101:6, pages 750-757.
Crossref
Crossref
Fernando Pastor, Pedro Berraondo, Iñaki Etxeberria, Josh Frederick, Ugur Sahin, Eli Gilboa & Ignacio Melero. (2018) An RNA toolbox for cancer immunotherapy. Nature Reviews Drug Discovery 17:10, pages 751-767.
Crossref
Crossref
Sandro Matosevic. (2018) Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies. Journal of Immunology Research 2018, pages 1-20.
Crossref
Crossref
Dennis C. HarrerJan DörrieNiels Schaft. (2018) Chimeric Antigen Receptors in Different Cell Types: New Vehicles Join the Race. Human Gene Therapy 29:5, pages 547-558.
Crossref
Crossref
Chu Lin & Jun Zhang. (2018) Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1869:2, pages 200-215.
Crossref
Crossref
Melita Cirillo, Peter Tan, Marian Sturm & Catherine Cole. (2018) Cellular Immunotherapy for Hematologic Malignancies: Beyond Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation 24:3, pages 433-442.
Crossref
Crossref
Rohtesh S. Mehta & Katayoun Rezvani. (2018) Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer. Frontiers in Immunology 9.
Crossref
Crossref
Yuan Hu, Zhi-gang Tian & Cai Zhang. (2017) Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Acta Pharmacologica Sinica 39:2, pages 167-176.
Crossref
Crossref
Kenneth DeSantes & Kimberly McDowell. 2018. Immunotherapy for Pediatric Malignancies. Immunotherapy for Pediatric Malignancies
175
215
.
Yui Harada, Koji Teraishi, Minori Ishii, Hiroshi Ban & Yoshikazu Yonemitsu. 2017. Natural Killer Cells. Natural Killer Cells.
Xianqiang Liu, Nan Zhang & Huan Shi. (2017) Driving better and safer HER2-specific CARs for cancer therapy. Oncotarget 8:37, pages 62730-62741.
Crossref
Crossref
Dominique Bollino & Tonya J. Webb. (2017) Chimeric antigen receptor–engineered natural killer and natural killer T cells for cancer immunotherapy. Translational Research 187, pages 32-43.
Crossref
Crossref
Fang Fang, Weihua Xiao & Zhigang Tian. (2017) NK cell-based immunotherapy for cancer. Seminars in Immunology 31, pages 37-54.
Crossref
Crossref
Congcong Zhang, Pranav Oberoi, Sarah Oelsner, Anja Waldmann, Aline Lindner, Torsten Tonn & Winfried S. Wels. (2017) Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity. Frontiers in Immunology 8.
Crossref
Crossref
Fabio E. Leal, Thomas A. Premeaux, Mohamed Abdel-Mohsen & Lishomwa C. Ndhlovu. (2017) Role of Natural Killer Cells in HIV-Associated Malignancies. Frontiers in Immunology 8.
Crossref
Crossref
S. V. Kulemzin, N. A. Chikaev, O. Y. Volkova, V. V. Kuznetsova, A. V. Taranin & A. A. Gorchakov. (2017) Modular lentiviral vector system for chimeric antigen receptor design optimization. Russian Journal of Bioorganic Chemistry 43:2, pages 107-114.
Crossref
Crossref
Maxim Shevtsov & Gabriele Multhoff. (2016) Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies. Frontiers in Immunology 7.
Crossref
Crossref
Rachel A. Burga, Tuongvan Nguyen, Jane Zulovich, Sarah Madonna, Loyda Ylisastigui, Rohan Fernandes & Eric Yvon. (2016) Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells. Cytotherapy 18:11, pages 1410-1421.
Crossref
Crossref
Annette Romanski, Christoph Uherek, Gesine Bug, Erhard Seifried, Hans Klingemann, Winfried S. Wels, Oliver G. Ottmann & Torsten Tonn. (2016)
CD
19‐
CAR
engineered
NK
‐92 cells are sufficient to overcome
NK
cell resistance in B‐cell malignancies
. Journal of Cellular and Molecular Medicine 20:7, pages 1287-1294.
Crossref
Crossref
Marcela V. Maus & Bruce L. Levine. (2016) Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. The Oncologist 21:5, pages 608-617.
Crossref
Crossref
John W Sessions, Dallin L Lindstrom, Brad W Hanks, Sandra Hope & Brian D Jensen. (2016) The effect of lance geometry and carbon coating of silicon lances on propidium iodide uptake in lance array nanoinjection of HeLa 229 cells. Journal of Micromechanics and Microengineering 26:4, pages 045002.
Crossref
Crossref
Garnet Suck, Marcus Odendahl, Paulina Nowakowska, Christian Seidl, Winfried S. Wels, Hans G. Klingemann & Torsten Tonn. (2015) NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunology, Immunotherapy 65:4, pages 485-492.
Crossref
Crossref
Fan Yang, Hao Jin, Jian Wang, Qian Sun, Cihui Yan, Feng Wei & Xiubao Ren. 2016. Progress in Cancer Immunotherapy. Progress in Cancer Immunotherapy
169
239
.
Elizabeth D. PraticoBryan J. FegerMichael J. WatsonBruce A. SullengerDawn E. BowlesCarmelo A. MilanoSmita K. Nair. (2015)
RNA-Mediated Reprogramming of Primary Adult Human Dermal Fibroblasts into c-kit
+
Cardiac Progenitor Cells
. Stem Cells and Development 24:22, pages 2622-2633.
Crossref
Crossref
John W. Sessions, Brad W. Hanks, Dallin L. Lindstrom, Sandra Hope & Brian D. Jensen. (2015) Transient Low-Temperature Effects on Propidium Iodide Uptake in Lance Array Nanoinjected HeLa Cells. Journal of Nanotechnology in Engineering and Medicine 6:4.
Crossref
Crossref
Mattias Carlsten & Richard W. Childs. (2015) Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications. Frontiers in Immunology 6.
Crossref
Crossref
Hans Klingemann. (2015) Challenges of cancer therapy with natural killer cells. Cytotherapy 17:3, pages 245-249.
Crossref
Crossref
B L Levine. (2015) Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells. Cancer Gene Therapy 22:2, pages 79-84.
Crossref
Crossref
Cristina Eguizabal, Olatz Zenarruzabeitia, Jorge Monge, Silvia Santos, Miguel Angel Vesga, Natalia Maruri, Arantza Arrieta, Marta Riñón, Estibaliz Tamayo-Orbegozo, Laura Amo, Susana Larrucea & Francisco Borrego. (2014) Natural Killer Cells for Cancer Immunotherapy: Pluripotent Stem Cells-Derived NK Cells as an Immunotherapeutic Perspective. Frontiers in Immunology 5.
Crossref
Crossref
Hua Jiang, Wenhao Zhang, Peipei Shang, Hui Zhang, Weijun Fu, Fei Ye, Tianmei Zeng, Hejing Huang, Xueguang Zhang, Wanping Sun, Daniel Man-Yuen Sze, Qing Yi & Jian Hou. (2013) Transfection of chimeric anti‐CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Molecular Oncology 8:2, pages 297-310.
Crossref
Crossref
Richard W. Childs & Maria Berg. (2013) Bringing natural killer cells to the clinic: ex vivo manipulation. Hematology 2013:1, pages 234-246.
Crossref
Crossref
Hans G. Klingemann. (2013) Cellular therapy of cancer with natural killer cells—where do we stand?. Cytotherapy 15:10, pages 1185-1194.
Crossref
Crossref
Peter M. Rabinovich & Sherman M. Weissman. 2013. Synthetic Messenger RNA and Cell Metabolism Modulation. Synthetic Messenger RNA and Cell Metabolism Modulation
3
28
.